Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine.

@article{Coelmont2006RibavirinAT,
  title={Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine.},
  author={Lotte Coelmont and Jan Paeshuyse and Marc Peter Windisch and Erik de Clercq and Ralf Bartenschlager and Johan Neyts},
  journal={Antimicrobial agents and chemotherapy},
  year={2006},
  volume={50 10},
  pages={
          3444-6
        }
}
Ribavirin antagonizes the in vitro anti-hepatitis C virus (HCV) activity of the pyrimidine nucleoside analogue 2'-C-methylcytidine, the active component of the experimental anti-HCV drug valopicitabine. In contrast, the combination of ribavirin with either the purine nucleoside analogue 2'-C-methyladenosine or the HCV protease inhibitor VX-950 resulted in an additive antiviral activity. These findings may have implications when planning clinical studies with valopicitabine. 

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).

VIEW 5 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

A three-dimensional model to analyze drug-drug interactions

  • M. N. Prichard, C. Shipman, Jr.
  • Antiviral. Res
  • 1990
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

In vitro selected Con1 subgenomic replicons resistant to 2 -C-methyl-cytidine or to R1479 show lack of cross resistance

  • S. Le Pogam, W.-R. Jiang, +11 authors I. Nájera
  • Virology
  • 2006
VIEW 1 EXCERPT

Antiviral efficacy of NS 3 - serine protease inhibitor BILN - 2061 in patients with chronic genotype 2 and 3 hepatitis C

  • H. Hinrichsen, Y. Benhamou, +6 authors G. G. Steinmann
  • Hepatology
  • 2005

Final phase I / II trial results for NM 283 , a new polymerase inhibitor for hepatitis C : antiviral efficacy and tolerance in patients with HCV - 1 infection , including previous interferon failures

  • E. Godofsky, J. Dienstag, +4 authors N. Brown
  • Hepatology
  • 2004